Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.
Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, Linch DC. Gale RE, et al. Among authors: linch dc. Blood. 2005 Nov 15;106(10):3658-65. doi: 10.1182/blood-2005-03-1323. Epub 2005 Aug 2. Blood. 2005. PMID: 16076872 Free article.
KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.
Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. Stringaris K, et al. Blood. 2016 Dec 15;128(24):2819-2823. doi: 10.1182/blood-2016-05-713099. Epub 2016 Oct 19. Blood. 2016. PMID: 27760759 Free PMC article.
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.
Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Kottaridis PD, et al. Among authors: linch dc. Blood. 2002 Oct 1;100(7):2393-8. doi: 10.1182/blood-2002-02-0420. Blood. 2002. PMID: 12239147 Free article.
Flt3 mutations and leukaemia.
Kottaridis PD, Gale RE, Linch DC. Kottaridis PD, et al. Among authors: linch dc. Br J Haematol. 2003 Aug;122(4):523-38. doi: 10.1046/j.1365-2141.2003.04500.x. Br J Haematol. 2003. PMID: 12899708 Free article. Review. No abstract available.
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon E, Burnett AK, Linch DC, Grimwade D; NCRI Adult Leukaemia Working Party. Gale RE, et al. Among authors: linch dc. Blood. 2005 Dec 1;106(12):3768-76. doi: 10.1182/blood-2005-04-1746. Epub 2005 Aug 16. Blood. 2005. PMID: 16105978 Free article.
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.
Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC; Medical Research Council Adult Leukaemia Working Party. Gale RE, et al. Among authors: linch dc. Blood. 2008 Mar 1;111(5):2776-84. doi: 10.1182/blood-2007-08-109090. Epub 2007 Oct 23. Blood. 2008. PMID: 17957027 Free article.
504 results